In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Proteomics Firms Turn to IT for Database Upgrade

Executive Summary

Proteomics companies don't want to be seen as database providers, a low-valuation model once pursued by Celera and Incyte. So companies like Myriad Genetics and Oxford GlycoSciences have spun out their database businesses into JVs with IT partners, which provide cash and technology. Both partners benefit: biotechs get valued as budding drug developers and retain access to these tools, while IT companies get a foot in the door of the life sciences markets into which they wish to expand their products and services.
Advertisement

Related Content

Terra Infirma: Pharma Dealmaking 2001
IBM Dives into the Life Sciences

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV001859

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel